Savran Technologies

Based in the Boston area, Savran Technologies is a biotechnology firm focused on developing non-invasive diagnostics. The company was founded in 2018 by Dr. Cagri Savran, who also serves as the CEO. Dr. Savran, a professor of Mechanical and Biomedical Engineering at Purdue University, invented the core technology, drawing on over 20 years of R&D experience that has resulted in 30 patents and applications. His academic journey includes a BS in Mechanical Engineering from Purdue University, followed by an MS and PhD in the same field from MIT. The impetus to commercialize his invention was supported by Purdue University's programs that encourage faculty to license their patents and create companies.

Savran Technologies is engineering systems to isolate ultra-rare cells from a standard blood test, a method sometimes referred to as a liquid biopsy. This technology has two primary applications currently under development: oncology and prenatal diagnostics. In oncology, the platform isolates Circulating Tumor Cells (CTCs) from blood, which can provide clinicians with insights into solid tumors for monitoring disease progression and predicting relapse. The system has been part of a Phase 2 clinical trial involving patients with triple-negative breast cancer. In prenatal diagnostics, the technology is being developed to capture fetal cells circulating in the maternal bloodstream. This allows for a comprehensive genetic picture of the fetus from a simple blood draw, offering a non-invasive method to access the intact fetal genome.

The company's core offering is a patented microfluidic platform designed for high-throughput cell separation. Unlike many microfluidic systems that process small sample volumes, Savran's technology can handle larger, milliliter-sized samples in minutes. This capability enables the rapid detection of extremely rare cells, on the order of one in a billion. Key features of the platform include a streamlined, centrifuge-free workflow, high capture efficiency of over 90%, and the ability to achieve near-100% purity with single-cell capture. The business operates in the biotechnology and non-invasive diagnostics markets, serving researchers and clinicians. To date, Savran Technologies has raised a total of $7.3M in funding through various rounds, including investments from entities like the Purdue Research Foundation.

Keywords: non-invasive diagnostics, liquid biopsy, rare cell detection, circulating tumor cells, CTC isolation, prenatal diagnostics, microfluidics, cell separation, cancer monitoring, genetic testing, fetal cell analysis, single-cell capture, Cagri Savran, Purdue University, cancer diagnostics, triple-negative breast cancer, biomarker detection, genomic analysis, high-throughput screening, medical diagnostics